
Another experimental drug meant to slow the damage of Alzheimer’s appears poised to join a growing arsenal of new treatments for this memory-robbing disease. In research published online Monday in the Journal of the American Medical Association and presented simultaneously at the Alzheimer’s Association International Conference in Amsterdam, the drug donanemab slowed memory and thinking… read on > read on >